Filing Flows › Lineage Cell Therapeutics (LCTX) › Royalties License and Other Revenues revenue
Lineage Cell Therapeutics (LCTX) Royalties License and Other Revenues revenue by quarter
Lineage Cell Therapeutics' Royalties License and Other Revenues revenue was $126K in Q2 2026 (second quarter 2026), -16% from Q1 2026. Over the last 7 quarters it ranged from $126K (Q2 2026) to $390K (Q4 2024).
| Quarter | Royalties License and Other Revenues revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $126K | -16% | -46% |
| Q1 2026 | $150K | -57% | -35% |
| Q4 2025 | $345K | +152% | -12% |
| Q3 2025 | $137K | -41% | — |
| Q2 2025 | $233K | +0.4% | — |
| Q1 2025 | $232K | -41% | — |
| Q4 2024 | $390K | — | — |
Q2 2026 at a glance
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Lineage Cell Therapeutics' Royalties License and Other Revenues revenue?
Lineage Cell Therapeutics' Royalties License and Other Revenues revenue was $126K in Q2 2026 (second quarter 2026), -16% from Q1 2026.
How has Lineage Cell Therapeutics' Royalties License and Other Revenues revenue changed?
Over the last 7 quarters it ranged from $126K (Q2 2026) to $390K (Q4 2024).
Q2 2026 results → · How Lineage Cell Therapeutics makes money →